Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumors.
Song Q, Yang B, Sheng W, Zhou Z, Zhang T, Qin B, Ji L, Li P, Wang D, Zhang X, Sun S, Zhang G, Zhao X, Gan Q, Xiong Q, Guan Y, Xia X, Yi X, Chen X, Guo W, Jiao S.
Song Q, et al. Among authors: xiong q.
Immunotherapy. 2022 May;14(7):553-565. doi: 10.2217/imt-2021-0105. Epub 2022 Mar 24.
Immunotherapy. 2022.
PMID: 35321561
Clinical Trial.